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Summary
Although androgen receptor (AR)-mediated signaling is central to prostate cancer, the ability to modulate AR signaling
states is limited. Here we establish a chemical genomic approach for discovery and target prediction of modulators of can-
cer phenotypes, as exemplified by AR signaling. We first identify AR activation inhibitors, including a group of structurally
related compounds comprising celastrol, gedunin, and derivatives. To develop an in silico approach for target pathway iden-
tification, we apply a gene expression-based analysis that classifies HSP90 inhibitors as having similar activity to celastrol
and gedunin. Validating this prediction, we demonstrate that celastrol and gedunin inhibit HSP90 activity and HSP90 clients,
including AR. Broadly, this work identifies new modes of HSP90 modulation through a gene expression-based strategy.Introduction
Androgen receptor (AR)-mediated signaling represents a critical
pathway in prostate cancer progression (Feldman and Feldman,
2001). Hormonal therapies that reduce circulating androgen
levels and inhibit theandrogen receptorwill initially blockprostate
cancer growth. Eventually, however, such therapies give rise to
fatal drug-resistant, or hormone-refractory, disease. Hormone-
refractory prostate cancers commonly show reactivation of AR-
mediated signaling through a number of mechanisms (Chen
et al., 2004; Feldman and Feldman, 2001; Linja et al., 2001). An-
drogen-independent tumors often show expression of AR and
of AR-induced genes such as PSA. Approximately one- to two-
fifths of androgen-independent tumors exhibit increased AR
expression after androgen ablation (Linja et al., 2001; Visakorpi
et al., 1995), and such AR overexpression appears to allow pros-
tate cancer growth in the face of decreased androgen levels
(Chenetal., 2004).Critically, overall expressionpatternsofandro-
gen-independent tumors are more similar to those of untreatedCANCER CELL 10, 321–330, OCTOBER 2006 ª2006 ELSEVIER INC. DOIandrogen-dependent primary cancers than to those of tumors
after neoadjuvant androgen deprivation, suggesting reactivation
of AR-mediated transcription (Holzbeierlein et al., 2004).
Though androgen signaling is critical to prostate cancer pro-
gression, our ability to modulate AR-mediated signaling pro-
grams is limited. Secondary hormonal therapies beyond andro-
gen ablation primarily target ligand-mediated activation of AR,
but none appear to be permanently effective against AR signal-
ing-mediated cancer progression (Lam et al., 2006). Additional
therapies are in development that may target both AR-mediated
signaling and cooperative signaling pathways. Heat shock pro-
tein 90 (HSP90) inhibitors, for example, suppress AR signaling
and other fundamental oncogenic pathways by promoting deg-
radation of hormone receptors, kinases, andother client proteins
(Whitesell and Lindquist, 2005). In general, the current lack of ef-
fective AR signaling inhibitors highlights the need for modulators
of AR signaling across the full spectrum of AR biology.
Discovery of compounds that modulate complex cancer
phenotypes such as androgen independence and signalingS I G N I F I C A N C E
Chemical genomics faces the twin challenges of discovering compounds that address complex biological phenotypes and elucidat-
ing compounds’ targets, once found. Androgen receptor (AR)-mediated signaling that is resistant to existing hormonal therapies rep-
resents one such phenotype. Here we apply a generalizable chemical genomic approach for discovering modulators of the AR-me-
diated signaling program in a prostate cancer cell model of hypersensitive AR signaling. We then develop a gene expression-based
method to identify the mechanism of a resulting compound family, using a gene expression compendium of well-characterized drug
activities. The utility of this chemical genomic approach is demonstrated by the discovery of two structurally andmechanistically novel
modulators of HSP90, a chaperone that stabilizes AR and many other oncogenic proteins.10.1016/j.ccr.2006.09.005 321
A R T I C L Erepresents a challenging problem in chemical biology. Gene ex-
pression-based chemical discovery has the potential to identify
compounds that convert one biological state, as defined by its
gene expression signature, to that of a more desirable state
without first assaying or identifying each critical effector in the
process (Stegmaier et al., 2004). In cancer biology, gene expres-
sion-based screening (GE-HTS) allows identification of com-
pounds that revert undesired oncogenic states to those of
more nonmalignant or drug-sensitive states. Broadly, gene ex-
pression-based chemical discovery represents a strategy for
identifying modulators of biological processes with little a priori
information about their underlying mechanisms.
An additional problem in chemical biology, perhaps more sig-
nificant than chemical discovery itself, is the identification of
compounds’ targets following cell-based discovery (di Bernardo
et al., 2005; Gardner et al., 2003). Recent work has applied un-
biased gene expression-based approaches to prediction of
chemical activity and targets in bacteria and yeast (di Bernardo
et al., 2005; Gardner et al., 2003; Parsons et al., 2004). Nonethe-
less, chemical genomic prediction has not been applied to com-
plex mammalian systems.
Here we illustrate a robust, generalizable approach for chem-
ical genomic discovery and prediction in mammalian cells.
Given the limited means available to identify modulators of crit-
ical AR signaling pathways and their mechanisms, we set out to
discover AR signaling inhibitors using a gene expression signa-
ture-based screening approach. Of the hits that emerged, celas-
trol and gedunin compounds represent a structurally similar
group of natural products with a history of medicinal and anti-
cancer use. To investigate the target activity of these com-
pounds, we used an approach to connect the activities of celas-
trol and gedunin to drugs with known biological activities at the
gene expression level, using a compendium of gene expression
profiles of drug treatment. Celastrol and gedunin both invoked
gene expression signatures highly similar to those of existing
HSP90 inhibitors. Subsequent work validated this gene expres-
sion-based activity prediction. However, celastrol and gedunin
do not act directly on the HSP90 ATP-binding pocket, unlike
most existing HSP90 inhibitors. Instead, they act synergistically
with existing HSP90 inhibitors to suppress HSP90 client signal-
ing and viability. In all, we demonstrate the discovery of HSP90
functional inhibition through a generalizable gene expression-
based approach for compound discovery and elucidation.
Results
Gene expression-based screen identifies inhibitors
of AR activation signature
Because of the paucity of effective AR-mediated signaling inhib-
itors, we set out to identify new inhibitors of AR activation using
a gene expression signature-based screening approach (Steg-
maier et al., 2004). GE-HTS identifies compounds that convert
a gene expression signature representing one state to that of an-
other, using a high-throughput bead-based method to quantify
the gene expression signatures (Figure 1A; Peck et al., 2006).
Here, we asked whether GE-HTS could be used to identify an-
drogen signaling modulators that revert the signature of the
androgen-activated state to the signature of the quiescent,
androgen-deprived state in prostate cancer cells.
Toward that end, we first defined the gene expression signa-
ture of AR activation in the LNCaP prostate cancer cell line,322a common in vitro model of AR-mediated signaling in prostate
cancer (Chen et al., 2004). The signature was defined by identi-
fying genes that are activated or repressed by androgen stimu-
lation (0.1 nMR1881, 24 hr) relative to androgen deprivation, us-
ing microarray-based gene expression profiling (Febbo et al.,
2005). The AR activation signature was refined to 27 genes
that showed robust activation or inhibition of expression upon
androgen stimulation as measured in our GE-HTS bead-based
assay (Figure 1B). The final 27 gene signature therefore repre-
sents a gene set that associates with androgen signaling at
a selected level of robustness.
Next, we asked whether the multigene GE-HTS approach
provides significant advantages over conventional screening
approaches for androgen signaling inhibitors. We found that
the GE-HTS method performed better than a single reporter
assay due to the robustness provided by a multigene readout.
Compared to a single-gene readout using the best marker
gene in the microarray data, the 27 gene signature decreased
the false-positive rate of our screen 14-fold and the false-nega-
tive rate 7-fold, as determined by leave-one-out crossvalidation
using weighted voting and K-nearest neighbors analysis (Table
S5 in the Supplemental Data available with this article online).
Further, GE-HTS allows the assay of endogenous AR-mediated
gene induction and repression, rather than expression in a non-
chromatin reporter system.
GE-HTS screening was then carried out for compounds that
convert the AR activation signature to the androgen-deprived
signature. Compound libraries comprising approximately 2500
compounds and enriched in drugs and natural products were
screened. LNCaP cells were treated for 24 hr with synthetic
androgen R1881 and compound for the GE-HTS screen. In par-
allel, the libraries were screened for their effects on LNCaP via-
bility over 3 days using a luminescent ATP quantitation assay.
The screen identified more than 20 compounds that robustly
suppress the androgen signaling signature without causing se-
vere toxicity in vitro, while another 30 were found tomildly inhibit
the signature (Table S1; Figures S1 and S2). Compounds that
inhibit the androgen signaling signature were identified using
three analytic metrics: summed gene expression, K-nearest
neighbors, and naive Bayes classification. These metrics incor-
porate both supervised and unsupervised approaches as well
as parametric and nonparametric statistics. Strong hits were de-
fined as compounds that induced the androgen deprivation sig-
nature in at least two of three replicates by all three measures at
p < 0.05. Weak hits were defined as compounds that induced
the androgen deprivation signature in at least two of three repli-
cates by only two measures (p < 0.05). These hits were subse-
quently filtered to remove compounds that inhibited cell growth
by more than 50% over 3 days.
Many of the identified androgen signaling signature inhibitors
have provocative activities. They include prazosin, a drug cur-
rently used for treatment of benign prostatic hyperplasia (Walsh,
1996), and the mTOR inhibitor rapamycin, which is currently in
clinical trials as a treatment for advanced prostate cancer
(Majumder and Sellers, 2005). Dexamethasone acetate was
also found to strongly inhibit the androgen signaling signature,
and a range of other glucocorticoids were identified as weak in-
hibitors; glucocorticoids are currently used for their systemic
effects in prostate cancer treatment but may also have a direct
effect on prostate cancer cell signaling (Lam et al., 2006). Most
notably, a large set of celastrol and gedunin natural productsCANCER CELL OCTOBER 2006
A R T I C L EFigure 1. Gene expression-based screen identifies inhibitors of androgen signaling signature
A:A high-throughput method for quantifying transcript levels was developed to enable gene expression signature-based screens. In this method, mRNA in cell
lysates is hybridized to dT20-conjugated plates and then reverse transcribed. The resulting covalently attached cDNA is amplified by ligation-mediated PCR.
For each gene to be assayed, ligation generates a sequence complementary to the transcript and flanked by a unique barcode tag and universal primer
sites. The ligation product is PCR amplified using biotin-conjugated universal primers. The PCR products are then captured by hybridization to probes comple-
mentary to the barcodes that are attached to uniquely colored polystyrene beads. The products are subsequently stained with streptavidin-phycoerythrin
(SAPE). Each gene product is identified by the color of its capture bead and quantified using the associated SAPE fluorescence, as measured by two-laser flow
cytometry.
B:A gene expression signature of androgen stimulation was defined from gene expression profiles of LNCaP cells stimulated with the synthetic androgen R1881
for 12 hr and 24 hr, as compared to androgen-deprived LNCaP cells. The 27 gene signature contains both androgen-induced and androgen-repressed
genes, shown here by row-normalized heat map.
C: GE-HTS screen identifies a family of celastrol and gedunin compounds that revert the androgen signaling signature to the androgen-deprived signature in
LNCaP cells. LNCaP cells were treated with 1 nM R1881 plus compounds atw20 mM for 24 hr. The heat map shows the row-normalized signatures induced by
gedunin and celastrol compounds in the screen and the competitive AR inhibitor casodex (bicalutamide).made upmore than a quarter of the identified AR signaling inhib-
itors (Figure 1C), and these compounds were therefore studied
in greater detail.
Celastrol, gedunin, and derivatives represent
a structurally similar group of natural products
that inhibit androgen signaling
The celastrol and gedunin triterpenoids represent a dominant
family of structurally similar compounds that emerged from
our GE-HTS screen (Figures 1C and 2A). Celastrol and sixCANCER CELL OCTOBER 2006gedunin derivatives showed strong inhibition of the androgen
signaling signature (Figure 1C), while two gedunin derivatives
and three celastrol derivatives also showed weak inhibitory ac-
tivity (Table S1). Celastrol and gedunin are natural products de-
rived from plants of the Celastracae and Meliacae families that
have been used therapeutically for several millennia, though
little is known about their cellular targets (Padma, 2005; Ushiro
et al., 1997). Celastrol and gedunin compounds show structural
similarity (Figure 2A; Figures S1A and S2A). Moreover, celastrol
and gedunin invoked similar global gene expression changes,323
A R T I C L EFigure 2. Celastrol and gedunin inhibit androgen signaling
A: Structures of celastrol and gedunin are shown (top). Derivatives of celas-
trol (left, bottom) and gedunin (right, bottom) identified as AR signature in-
hibitors by GE-HTS are also shown.
B: Celastrol and gedunin inhibit the GE-HTS androgen signaling signature in
a concentration-dependent manner. LNCaP cells were treated with 1 nM
R1881 for 12 hr and then 1 nM R1881 plus compound for an additional 24
hr. Controls were treated with vehicle in place of R1881 and/or compound.
The row-normalized GE-HTS signature shows concentration-dependent re-
version to the androgen deprivation signature.
C: Celastrol- and gedunin-mediated effects on androgen-responsive gene
expression mimics androgen deprivation. Average link hierarchical cluster-
ing was carried out on androgen-responsive gene expression from andro-
gen-deprived cells (green) and androgen-treated cells with vehicle (red),
celastrol (1.25 mM, 24 hr, blue), or gedunin (20 mM, 24 hr, yellow). The dendro-
grams show the clustering of the samples within the androgen-responsive
gene space.
D: Celastrol and gedunin inhibit anchorage-independent prostate cancer
cell growth. Celastrol and gedunin inhibit LNCaP colony formation in soft
agar (mean of three replicates 6 1 SD).
E: Celastrol and gedunin inhibit adherent prostate cancer cell growth. Ce-
lastrol (red) and gedunin (black) inhibit growth of LNCaP cells, as deter-
mined by luminescent assay of ATP level (mean of four replicates 6 1 SD).324when we assayed the gene expression effects of celastrol (1.25
mM, 6 hr) and gedunin (20 mM, 6 hr) by genome-wide DNAmicro-
array. The genes regulated by celastrol and gedunin were highly
overlapping (p < 10218, Fisher’s exact test; see Supplemental
Data). Celastrol, gedunin, and their derivatives therefore repre-
sent a family of AR signaling inhibitors with similar structure
and activity at the gene expression level.
To validate the effect of celastrol and gedunin on AR-
mediated signaling, we first established that they inhibit the
GE-HTS androgen signaling signature in a concentration-
dependent manner in LNCaP cells (Figure 2B). Because natural
products often contain impurities, we verified that celastrol and
gedunin used for this work were >98% and >99% pure, respec-
tively, by HPLC and NMR. Celastrol- and gedunin-induced inhi-
bition was seen both with and without 12 hr pretreatment with
androgen (Figure 2B and data not shown). Celastrol and gedunin
therefore inhibit the androgen signaling signature outside the
screen context.
We next asked whether celastrol and gedunin inhibit the
broader programof androgen signaling beyond theGE-HTS sig-
nature. To address this question, we compared the genome-
wide gene expression profiles of androgen-stimulated LNCaP
cells treated with celastrol (1.25 mM) and gedunin (20 mM) for
24 hr to those of androgen-stimulated and androgen-deprived
cells. Hierarchical clustering indicated that androgen-respon-
sive gene expression (Febbo et al., 2005) of compound-treated
androgen-stimulated cells is more similar to that of androgen-
deprived cells than to that of vehicle-treated androgen-stimu-
lated cells (Figure 2C). Celastrol and gedunin treatment there-
fore invoked a broader gene expression program similar to
that induced by androgen deprivation, though differences be-
tween them can still be seen.
To investigate the cellular consequences of celastrol- and ge-
dunin-mediated inhibition, we assessed whether celastrol and
gedunin activity results in decreased cell growth, consistent
with AR inhibition. First, we determined whether the compounds
inhibit adherent growth of androgen-stimulated LNCaP cells
by luminescent assay of ATP levels. The compounds mimic
the growth-inhibitory effects of androgen deprivation around
the EC50 of androgen signaling inhibition (Figures 2D and 2E).
Second, the compounds’ effects on anchorage-independent
growth of LNCaP cells was assayed in soft agar (Figure 2D).
Celastrol (0.625 mM) and gedunin inhibited anchorage-indepen-
dent growth to a similar degree as the AR competitive antago-
nist bicalutamide (casodex). In addition to reducing colony num-
ber, celastrol and gedunin inhibited colony size (data not
shown). Celastrol and gedunin therefore inhibit adherent and an-
chorage-independent growth of LNCaP cells, likely, in part, due
to suppression of AR signaling.
Gene expression compendium of drug effects identifies
HSP90-inhibitory activity of celastrol and gedunin
While celastrol and gedunin clearly inhibit AR-mediated signal-
ing, their target andmechanism are not obvious. Indeed, amajor
challenge in cell-based chemical biology and chemical geno-
mics is the identification of compounds’ targets (Gardner
et al., 2003). We hypothesized that gene expression signatures
could be used to identify compound action based on the similar-
ity of such compound-induced signatures to signatures of exist-
ing drugs of known mechanism. We therefore employed
a collection of gene expression profiles of drug-treated cell linesCANCER CELL OCTOBER 2006
A R T I C L Ethat was developed in our lab, termed the Connectivity Map
(Lamb et al., 2006). This database comprises 453 genome-
wide Affymetrix expression profiles derived from the treatment
of human cell lines with 164 small molecules, primarily FDA-
approved drugs. A 6 hr treatment time was chosen in an attempt
to capture the primary, and potentially mechanistic, effects of
the compounds rather than the downstream phenotypic conse-
quences.
In order to use the Connectivity Map to gain insight into celas-
trol and gedunin function, we first defined a gene expression
signature of celastrol and gedunin activity. The expression sig-
natures of celastrol and gedunin were derived by expression
profiling of RNA from LNCaP cells treated with celastrol (1.25
mM), gedunin (20 mM), and vehicle (DMSO) for 6 hr; signatures
were defined using comparative marker selection to identify
transcripts that distinguished between the compound- and
vehicle-treated profiles by the signal-to-noise (SNR) metric. The
enrichment of these signatures in the gene expression profiles
of the Connectivity Map database was then assessed using
a gene enrichment metric, the connectivity score, based on
the Kolmogorov-Smirnov statistic (Lamb et al., 2003). Out of
164 compounds represented by the Connectivity Map, celastrol
was the top match for the gedunin signature and the fourth-
ranked match for the celastrol signature (Table S2). The enrich-
ment of the LNCaP celastrol signature in the MCF7 celastrol
gene expression profile validates our ability to identify true sim-
ilarities using the Connectivity Map and their cell line indepen-
dence. Moreover, the enrichment of the gedunin signature in
the celastrol profile demonstrates similarity between celastrol
and gedunin activities.
To generate hypotheses regarding celastrol and gedunin tar-
gets, the Connectivity Map was used to identify known drugs
with highly similar gene expression effects. The celastrol and
gedunin signatures showed very strong similarity to the gene
expression profiles of four HSP90 inhibitors: geldanamycin
(n = 6), 17-dimethylaminoethylamino-17-demethoxy-geldana-
mycin (17-DMAG; n = 2), 7-allylamino-17-demethoxygeldana-
mycin (17-AAG; n = 18), and monorden (radicicol; n = 10)
(Figure 3A; Table S2). Geldanamycin and its derivatives induced
gene expression profiles that were highly enriched with celastrol
and gedunin signature genes at 6 hr, as shown by the high en-
richment score ranking of these compounds relative to other
compounds in the Connectivity Map database (Figure 3A). For
example, celastrol- and gedunin-induced genes were enriched
in the 17-AAG profile (Figure 3B, green), whereas celastrol- and
gedunin-repressed genes were similarly repressed by 17-AAG
(Figure 3B, red). In contrast, a signature of randomly selected
genes did not show enrichment over this 17-AAG profile
(Figure 3B). The radicicol profiles were similarly enriched, albeit
to a lesser extent (data not shown). The similarity of celastrol
and gedunin activities to HSP90 inhibition is supported by the
significant number of replicates (Figure 3A, single instances)
and the number of different HSP90 inhibitors (Figure 3A, com-
bined instances) that show this enrichment. The signatures of
24 hr celastrol and gedunin treatment also showed similarity
to the HSP90 inhibitor profiles, though to a somewhat lesser de-
gree (data not shown). HSP90 inhibition therefore represents
a major gene expression signature invoked by celastrol and ge-
dunin. More generally, this work illustrates a robust approach
for using gene expression signatures to gain insight into chem-
ical activity.CANCER CELL OCTOBER 2006Celastrol and gedunin inhibit the HSP90 pathway
Having used the Connectivity Map to generate the hypothesis
that celastrol and gedunin function as HSP90 inhibitors, we
next sought to validate this hypothesis. Since AR is an HSP90
client protein, celastrol- and gedunin-mediated inhibition of
HSP90 could explain the observed suppression of androgen
signaling. HSP90 inhibition induces degradation of AR and other
client proteins and thereby targets multiple, cooperative onco-
genic signaling pathways.
We first asked whether celastrol and gedunin decrease the
levels of AR itself. Both celastrol and gedunin were found to de-
crease AR protein levels in a concentration-dependent manner
(Figure 4A). Celastrol decreased AR levels in LNCaP cells at
0.5 mM and above, while gedunin decreases their levels at 10
mM and above. Almost complete ablation of AR levels was
seen at 1 mM celastrol and 20 mM gedunin. These concentra-
tion-dependent effects on AR are consistent with the observed
Figure 3. Gene expression compendium of drug treatment predicts HSP90-
inhibitory activity of celastrol and gedunin
A: Celastrol and gedunin gene expression signatures are similar to the gene
expression profiles of HSP90 inhibition. From a collection of gene expression
profiles representing 164 compounds, the expression profiles of 17-AAG,
17-DMAG, and geldanamycin treatment (6 hr, MCF7) show enrichment of
celastrol (1.25 mM, 6 hr, LNCaP) and gedunin (20 mM, 6 hr, LNCaP cells) sig-
natures at 6 hr. The barview is constructed from 453 horizontal lines, each
representing an individual treatment instance and ordered by their
corresponding enrichment with the celastrol and gedunin query signatures.
All geldanamycin (n = 6), 17-allylamino-geldanamycin (n = 18), and 17-di-
methylamino-geldanamycin (n = 2) instances are colored in black. Colors
applied to the remaining instances reflect positive (green), negative (red),
or no (gray) enrichment with the celastrol and gedunin query signatures.
The combined barview is constructed from horizontal lines, each represent-
ing a compound treatment and ordered as for the single instance barview.
B: Enrichment of the celastrol and gedunin signatures in a selected 17-AAG
instance. Celastrol and gedunin induce (green) and repress (red) gene
probes that are enriched in the 17-AAG gene expression profile (22,283
probe sets), ordered by their extent of differential expression between treat-
ment and control scans for the 17-AAG instance (x axis). The Kolmogorov-
Smirnov score is shown for the induced and repressed signatures of celastrol
(1.25 mM, 6 hr, LNCaP) and gedunin (20 mM, 6 hr, LNCaP) across the best
matched 17-AAG gene expression profile (1 mM, 6 hr, MCF7). The fact that
most celastrol- and gedunin-induced genes appear early in the ordered
17-AAG profile and are therefore enriched in the 17-AAG-induced signature
is illustrated by this graphical representation of the Kolmogorov-Smirnov
analysis (green). The converse is true for the repressed genes (red). A signa-
ture populated with randomly selected probe sets shows no enrichment.325
A R T I C L EFigure 4. Celastrol and gedunin inhibit the HSP90 pathway
A: Celastrol and gedunin lower HSP90 client protein levels. Celastrol and gedunin induce concentration-dependent decreases in AR level at 24 hr. 17-AAG
treatment is shown as a positive control.
B:Celastrol and gedunin decrease the levels of HSP90 clients BCR-ABL1, EGFR, and FLT3. Celastrol and gedunin treatment for 24 hr lowers EGFR levels in LNCaP
cells, BCR-ABL1 levels, and phosphorylation in K562 cells, and FLT3, EGFR, and BCR-ABL1 levels in Ba/F3 cells. Ba/F3 cells overexpressing BCR-ABL1 were par-
ticularly susceptible to death upon celastrol treatment, resulting in lowered total protein level at 7.5 mM celastrol.
C: Cellular treatment with celastrol and gedunin inhibits HSP90 ATP-binding activity. HSP90 from lysates of celastrol- or gedunin-treated LNCaP and K562 cells
show decreased binding to ATP-polystyrene relative to vehicle-treated cells. ATP-binding proteins were isolated from treated LNCaP and K562 cells by ATP
affinity purification and detected by western blot. Affinity-purified proteins (pulldown) and total lysate were blotted for HSP90a, control ATP-binding proteins
CSK (LNCaP), DDR1 (K562), and actin.
D:Celastrol decreases HSP90 interaction with its cochaperone p23. Celastrol treatment of SKBR-3 cells (2.5 mM, 12 hr) decreased the amount of p23 that coim-
munoprecipitated with HSP90, as shown by western blot of the coimmunoprecipitate and lysate. Celastrol did not affect the amount of coimmunoprecipitat-
ing HOP, shown as a control. The C-terminal HSP90 inhibitor PU24FCI (20 mM, 24 hr) is shown as a control.inhibitory effects on AR-mediated signaling. Notably, HSP90 in-
hibitors 17-AAG and geldanamycin suppressed the androgen
signaling signature as well (data not shown).
To more broadly establish the effects of celastrol and gedunin
on the HSP90 pathway, we tested whether these compounds
decrease the protein levels of other HSP90 clients. Celastrol
and gedunin treatment lowered the protein levels of FLT3,
EGFR, and BCR-ABL1 in a concentration-dependent manner
in several cell lines (Figure 4B). These findings demonstrate
that celastrol and gedunin decrease the levels of a range of
HSP90 client proteins.
Given their inhibition of HSP90 clients, we next asked whether
celastrol and gedunin affect HSP90 activity itself. To assess the
effects on HSP90 activity within a cellular context, we treated
LNCaP and K562 cells with celastrol or gedunin for 24 hr and
subsequently tested the cellular HSP90’s ATP-binding activity.
ATP-binding activity was assayed by ATP-polyacrylamide pull-
down of HSP90 from cell lysates, followed by western blot-
based quantification (Bali et al., 2005). This assay identifies
HSP90 inhibition, both direct and indirect, that alters HSP90
ATP-binding activity in cell lines (Bali et al., 2005; Soti et al.,
2002). We found that celastrol and gedunin treatment inhibited326the ATP-binding activity of HSP90a in both cell lines (Figure 4C).
In contrast, compound treatment did not affect the ATP-binding
activity of the kinases CSK and DDR1, which are not HSP90 cli-
ents. The decrease in ATP binding by HSP90 cannot be ac-
counted for by changes in HSP90 level (Figure 4C). Celastrol
and gedunin therefore inhibit HSP90 activity itself in a cellular
context, either directly or indirectly.
Celastrol, as the more potent compound, was then tested for
effects on HSP90’s functional interactions with cochaperones.
Consistent with its reduction of HSP90 ATP-binding activity, ce-
lastrol treatment reduced HSP90 interaction with the cochaper-
one p23 in SKBR-3 cells, as determined by coimmunoprecipita-
tion with HSP90 (Figure 4D). The N-terminal inhibitor PU-H71
(He et al., 2006; Vilenchik et al., 2004) had the same effect.
p23 interacts with the ATP-bound form of HSP90 and helps sta-
bilize the mature steroid receptor-HSP90 complex (Felts and
Toft, 2003). Geldanamycin and other HSP90 inhibitors are
known to inhibit p23 association with HSP90 (Felts and Toft,
2003). In contrast, HSP90-HOP interaction was unaltered by
celastrol and other HSP90 inhibitors (Figure 4D). Thus, celastrol
inhibits the functional interactions of HSP90 and suppresses
HSP90 client levels.CANCER CELL OCTOBER 2006
A R T I C L ECelastrol and gedunin modulate HSP90 activity by
a mechanism that is distinct from that of existing
HSP90 ATP-binding pocket inhibitors
Since celastrol and gedunin inhibit HSP90 pathway function, we
asked whether celastrol and gedunin act by competitively bind-
ing to the ATP-binding pocket of HSP90, the mechanism com-
mon to most HSP90 inhibitors (Whitesell and Lindquist, 2005).
We first tested whether celastrol or gedunin could compete
with Cy3B-geldanamycin for binding to the ATP-binding pocket
of purified HSP90a by fluorescence polarization assay (Kim
et al., 2004; Llauger-Bufi et al., 2003). In contrast to the earlier
ATP-binding activity assay, this experiment tested the ability
of celastrol and gedunin to directly inhibit small molecule bind-
ing to the ATP pocket of purified HSP90 when combined in vitro.
Neither celastrol nor gedunin significantly competed with gelda-
namycin binding to recombinant HSP90a at concentrations up
tow100 mM, with compound addition before and after geldana-
mycin addition (Figure 5A). The N-terminal inhibitors 17-AAG
and PU-H71, on the other hand, competed with geldanamycin
binding at low concentrations in vitro (Figure 5A) (He et al.,
Figure 5. Celastrol and gedunin inhibit HSP90 function through a different
mechanism than existing HSP90 ATP-binding pocket inhibitors
A: Celastrol (black squares) and gedunin (black upward triangles) do not
compete with Cy3B-labeled geldanamycin for binding to the ATP-binding
site of HSP90a in vitro at pharmacological doses, unlike N-terminal inhibitors
17-AAG (black downward triangles) and PU-H71 (black diamonds). The de-
crease in fluorescence polarization of Cy3B-geldanamycin upon displace-
ment from the ATP-binding pocket of recombinant hHSP90a is shown. The
novobiocin-analog coumermycin A (white squares) is shown as a C-termi-
nal binding control. The mean 6 1 SD is shown.
B: Celastrol and gedunin show synergistic inhibition of AR signaling with the
HSP90 inhibitor 17-AAG. The combined effect of these compounds and
17-AAG on the LNCaP androgen signaling signature at 24 hr is shown by iso-
bologram. Synergy appears as points below the line of additivity.
C: Celastrol and gedunin show synergistic growth inhibition with 17-AAG.
The combined effect of these compounds and 17-AAG on LNCaP cell via-
bility at 24 hr, as determined by ATP level, is shown by isobologram.CANCER CELL OCTOBER 20062006; Vilenchik et al., 2004). These results indicate that celastrol
and gedunin act on HSP90 by a different mechanism than exist-
ing N-terminal HSP90 inhibitors.
If celastrol and gedunin act on HSP90 function via a distinct
mechanism from HSP90 ATP-binding site inhibition (Bagatell
et al., 2005), they might act synergistically with existing HSP90
inhibitors. We therefore tested the combinatorial effects of these
compounds with HSP90 inhibitors on HSP90 client signaling
and viability. We found that celastrol and gedunin show mild
synergy with geldanamycin and 17-AAG in inhibiting the andro-
gen signaling signature, as shown by isobologram analysis
(Figure 5B; Figure S3). Celastrol and gedunin also synergistically
inhibit cell growth, assayed by ATP level, with geldanamycin and
17-AAG at low concentrations (Figure 5C; Figure S3). Celastrol
and gedunin therefore act synergistically with existing modes
of HSP90 ATP-binding site inhibition to inhibit HSP90 client
signaling and viability in a cellular context, consistent with their
inhibition of HSP90 via a distinct mechanism.
Discussion
Chemical genomics has the potential to identify modulators of
complex cancer phenotypes and predict their activities with little
prior knowledge about the underlying mechanisms. Here we re-
port a chemical genomic screen for modulators of AR-mediated
signaling modulators, a critical cancer signaling pathway. To in-
vestigate the activity of the resulting celastrol and gedunin family
of hits, a gene expression-based approach was used to identify
similar known drug activities and predicted that these com-
pounds act as HSP90 pathway inhibitors. We then validated
this hypothesis by demonstrating that celastrol and gedunin de-
stabilize HSP90 clients including AR and inhibit HSP90 function.
Moreover, celastrol and gedunin act outside the HSP90 ATP-
binding pocket targeted by most HSP90 inhibitors and act syn-
ergistically with these inhibitors.
Given the central role that HSP90 and its clients play in cancer
biology, celastrol and gedunin compounds represent a signifi-
cant new set of HSP90 pathway modulators. The work pre-
sented here identifies celastrol- and gedunin-mediated inhibi-
tion of HSP90 client activity including AR (Yang et al., 2006)
and illustrates its broad downstream effects on AR-regulated
gene expression (Georget et al., 2002; Waza et al., 2005). Celas-
trol and gedunin are further shown to affect HSP90 activity and
interactions. The decrease in HSP90’s ATP-binding activity and
HSP90-p23 interaction could result from a shift to the ADP
complexed form of HSP90, which directs client proteins to the
proteasome (Bali et al., 2005; Felts and Toft, 2003; Soti et al.,
2002). Indeed, celastrol treatment is known to cause accumula-
tion of ubiquitinated proteins (Yang et al., 2006); such accumu-
lation can result from HSP90 inhibition and stress response, and
the subsequent redirection of proteins through the proteasomal
pathway (Mimnaugh et al., 2004). Consistent with HSP90-inhib-
itory activity, celastrol has also been shown to induce HSP70
levels (Westerheide et al., 2004), a hallmark of HSP90 inhibition
by existing ansamycin antibiotic HSP90 inhibitors as well as
stress and heat shock response (Murakami et al., 1991). Celas-
trol has additionally been shown to suppress hERG potassium
channel activity by inhibiting hERG maturation (Sun et al.,
2006), which is seen with existing HSP90 inhibitors and is hy-
pothesized to result from HSP90 inhibition (Ficker et al., 2003).
Both celastrol and existing HSP90 inhibitors appear to be active327
A R T I C L Ein neurodegenerative disease models (Wang et al., 2005; Waza
et al., 2005) where, notably, 17-AAG inhibits neurodegeneration
induced by polyglutamine expansion of AR. Last, both celastrol
and gedunin also have noted antimalarial activity, as have other
HSP90 inhibitors (Figueiredo et al., 1998; MacKinnon et al.,
1997). These observations can be unified by the present discov-
ery of celastrol and gedunin’s HSP90-inhibitory activity.
Celastrol and gedunin compounds have the potential to pro-
vide new modes of HSP90 inhibition. Celastrol and gedunin
act outside the N-terminal ATP-binding pocket of HSP90 and
therefore inhibit HSP90 function by a mechanism that is distinct
from that of most existing HSP90 inhibitors. Few compounds in-
hibit HSP90 through mechanisms outside this N-terminal do-
main (Bali et al., 2005; Kovacs et al., 2005; Marcu et al., 2000).
Only two other existing drugs, cisplatin and novobiocin, act
directly on HSP90 outside this fold by binding the C-terminal
domain, and even these only induce HSP90 inhibition at high
concentrations at which other mechanisms of action likely
predominate (Marcu et al., 2000; Whitesell and Lindquist,
2005). While our work demonstrates that celastrol and gedunin
inhibit HSP90 function by acting outside the ATP-binding
pocket, it remains to be determined whether they act directly
or indirectly on HSP90. Induction of heat shock response or
other regulatory mechanisms could, for example, indirectly in-
hibit HSP90 function. Future work may address the mechanistic
details of this HSP90 modulation.
Because celastrol and gedunin inhibit HSP90 function through
a different mechanism than N-terminal HSP90 inhibitors, celas-
trol and gedunin compounds may have significant therapeutic
and scientific potential. Triterpenoid derivatives of the celastrol
and gedunin family compounds may serve as a starting point
for development of drugs that prove useful both in combination
with existing HSP90 inhibitors or alone, in the advent of resis-
tance against existing inhibitors. Scientifically, celastrol and ge-
dunin may afford further insight into HSP90 biology by providing
tools to probe HSP90 function; several significant HSP90 inter-
actors have been discovered through synthetic screens for
genes that confer hypersensitivity to geldanamycin-mediated in-
hibition, for example (Zhao et al., 2005). Thus, celastrol and ge-
dunin offer a unique window into HSP90 inhibition with broad
therapeutic and scientific possibilities.
Beyond HSP90 modulation, this work addresses a significant
problem in chemical biology: the discovery of modulators of
complex cancer phenotypes and the molecular activities under-
lying these modulators. We have demonstrated a combined
chemical genomic approach to compound discovery and char-
acterization based wholly on gene expression. This strategy
provides a useful endpoint for drug and activity screening, since
assaying associative effects can serve as a proxy for assaying
causal effects. Nonetheless, the strength of the gene expres-
sion, as opposed to other readouts, as an assay may vary de-
pending on the biology underlying the state being studied.
Significantly, we have applied a robust approach for chemical
activity prediction that uses gene expression signature enrich-
ment analysis to identify similar known drug activities. Compen-
dia of gene expression profiles have been previously used to
identify gene targets of drug perturbations in both bacteria
(Gardner et al., 2003) and yeast (di Bernardo et al., 2005; Hughes
et al., 2000; Parsons et al., 2004), but such work has not
previously been extended to mammalian systems. The ap-
proach presented here identifies a target pathway of two328uncharacterized compounds in a manner robust to ad hoc ex-
perimental decisions including cell context and treatment pa-
rameters. Notably, though some connectivity is dependent
upon appropriate context (for example, estrogen signaling re-
quiring estrogen receptor expression), there appears to be cell
line independence in the majority of the cases examined
(Lamb et al., 2006). One caveat to this approach is that it re-
quires that the activity of query compounds be represented
among the profiled drug activities. Our approach additionally
may not distinguish between direct and indirect compound ac-
tivities in all cases, though this may afford a nuanced view. In
sum, this work demonstrates a promising chemical genomic
strategy for discovering modulators of complex cancer pheno-
types and subsequently establishing theirmechanismsof action.
Experimental procedures
Reagents and cell lines
Celastrol (Calbiochem) and gedunin (Gaia Chemicals) were solubilized in
DMSO. LNCaP.FGC cells (ATCC) were grown in RPMI 1640 (ATCC) with
10% FBS. Ba/F3 cells stably expressing human FLT3, EGFR, and BCR-
ABL1 were grown in RPMI 1640, 10% FBS, and 2 ng/ml IL-3. SKBr3 cells
were grown in a 1:1 DME:F12 plus 10% FBS.
Gene expression profiling and analysis
The mRNA expression profiles of celastrol- and gedunin-treated cells were
determined by Affymetrix U133A microarray analysis in triplicate. RNA was
isolated by Trizol extraction from LNCaP cells treated with vehicle, 1.25 mM
celastrol, or 20 mM gedunin (1) for 24 hr in RPMI, 10% charcoal-stripped
FBS, and 1 nM R1881 or vehicle, following androgen deprivation in char-
coal-stripped media for 2 days, and (2) for 6 hr in RPMI with 10% FBS. IVT,
labeling, hybridization, and washing were carried out on the Affymetrix
High-Throughput Array platform using HT_HG-U133A preproduction arrays
(early access version; part number 520276) for all but the 24 hr gedunin sam-
ples. U133A version 2 arrays were used for the 24 hr gedunin samples for
technical reasons. Raw data were processed by RMA (Table S6). For hierar-
chical clustering, a 169 probe set of androgen-regulated genes was defined
and used to perform average linkage clustering (Supplemental Experimental
Procedures). Raw data are available at http://www.broad.mit.edu/cgi-bin/
cancer/publications/pub_menu.cgi/ and NCBI’s Gene Expression Omnibus
(GEO; http://www.ncbi.nlm.nih.gov/geo/; accession numbers GSE5505 to
GSE5508).
Gene expression signature analysis
Androgen signaling signature
The androgen signaling signature was developed from independent Affyme-
trix U133A profiles of LNCaP cells treated with 0.1 nM R1881 over a 24 hr
time course (Febbo et al., 2005). Class neighbors analysis was used to iden-
tify genes that are differentially expressed upon R1881 androgen treatment
relative to vehicle by the SNR metric (Golub et al., 1999; Reich et al.,
2006). The top marker genes were tested for differential expression between
androgen-stimulated and -deprived states by GE-HTS assay. The 27 genes
with the most robust discrimination by SNR were chosen for the GE-HTS an-
drogen signaling signature (Table S3). Two normalization controls, SRP72
and KIAA0676, were selected from genes with moderate expression levels
that varied little over the R1881 time course.
Celastrol and gedunin signatures
The celastrol and gedunin signatures were developed from RMA-processed
microarray data from LNCaP cells treated with 1.25 mMcelastrol or 20 mMge-
dunin for 6 hr. Comparative marker selection was used to identify markers
that distinguished celastrol- and/or gedunin-treated samples from vehicle-
treated samples by the median SNR (Golub et al., 1999). The top 50 markers
that increased and decreased relative to vehicle-treated controls were used
as the signatures (Table S7).
GE-HTS androgen signaling signature assay
The GE-HTS assay was carried out as described (Peck et al., 2006 and Sup-
plemental Data) using AR signature probes (Table S3).CANCER CELL OCTOBER 2006
A R T I C L EGE-HTS and viability screens
NINDS, Biomol, and SpecPlus libraries (http://www.broad.mit.edu/chembio/
platform/screening/compound_libraries/index.htm/) were screened using
GE-HTS androgen signaling and viability assays. After 2 days androgen dep-
rivation, LNCaP cells were treated with compounds (w20 mM) or vehicle
(DMSO) plus 1 nM R1881 for 24 hr for the GE-HTS screen and for 3 days
for the viability screen. Raw GE-HTS expression levels were filtered and nor-
malized (Table S8) as described in the Supplemental Experimental Proce-
dures. Compounds were scored by weighted and unweighted ‘‘summed
score’’ metrics, KNN classifier, and naive Bayes classifier to identify candi-
date modulators that induced the androgen deprivation signature (Supple-
mental Experimental Procedures). For heat map visualization, screen data
were normalized between libraries using themean SRP72 value of the andro-
gen-deprived vehicle controls (Table S9).
Viability and soft agar assays
Adherent cell growth was measured by luminescent assay of ATP level (Cell-
TiterGlo, Promega). LNCaP cells were grown in charcoal-stripped media for
2 days prior to simultaneous treatment with 1 nM R1881 and the relevant
compound. Synergy was assessed by analyzing the IC50 of one drug over
a range of concentrations of the other drug and vice versa. The resulting con-
centration pairs were visualized by isobologram (Gessner, 1995). Anchorage
independence was measured by soft agar assay (Hahn et al., 1999). Com-
pounds were added to both agar layers. Colonies were scored after 3 weeks.
Connectivity Map analysis for drug activity
The current version of the Connectivity Map data set (build01) contains ge-
nome-wide expression data for 453 treatment and vehicle control pairs, rep-
resenting 164 distinct small molecules. Cell treatments and Affymetrix profil-
ing were predominantly carried out in MCF7 cells with 6 hr treatments as
detailed (Table S4) (Lamb et al., 2006). Enrichment of the induced and re-
pressed genes of a signature within each Connectivity Map treatment profile
was estimated with a metric based on the Kolmogorov-Smirnov statistic as
described (Lamb et al., 2003, 2006). Connectivity Map data are available at
http://www.broad.mit.edu/cmap/ and GEO (accession number GSE5258).
Western blotting
Western blotting was carried out as described (Ebert et al., 2005). The follow-
ing antibodies were used: AR N-20 (1:250, sc-816, Santa Cruz), EGFR
(1:1000, CST2232, Cell Signaling), ABL (1:1000, CST2862, Cell Signaling),
phospho-tyrosine 4G10 for P-BCR-ABL1 (05-321, Upstate), FLT3/FLK2 S-18
(1:1000, sc-480, Santa Cruz), HSP90a (1:250, Stressgen, SPS-771F),
HSP90 (1:5000, Abcam), CSK H-75 (1:250, Santa Cruz, sc-13074x), DDR1
H-126 (1:250, Santa Cruz, sc-8988x), hHSP90 H9010, Hop F5, and p23
JJ3, tubulin (1:5000, Abcam, ab6046), and actin (1:5000, Abcam, ab8227-50).
HSP90 ATP-binding assay
The ATP-binding assay was similar to that in previous reports (Bali et al.,
2005; Soti et al., 2002). LNCaP and K562 cells were treated with celastrol
and gedunin for 24 hr and then lysed in TNESV buffer (50 mM Tris, 2 mM
EDTA, 100 nM NaCl, 1 mM activated sodium orthovanadate, 25 mM NaF,
1% Triton X-100 [pH 7.5]) for 30 min at 4C. Lysates were spun for 30 min
at 12,000 rpm at 4C. Protein (200 mg) was incubated with conditioned
g-ATP-polyacrylamide resin (Novagen) in incubation buffer (10 mM Tris-
HCl, 50 mM KCl, 5 mMMgCl2, 20 mM Na2MoO4, 0.01% Nonidet P-40) over-
night at 4C, rotating. The resin was then washed four times with incubation
buffer. Bound proteins were isolated by boiling with SDS buffer.
HSP90 coimmunoprecipitation
SKBR-3 cells were treated with vehicle, celastrol (2.5 mM, 12 hr), and
PU24FCI (20 mM, 24 hr) (Vilenchik et al., 2004). Cells were lysed in 20 mM
Tris HCl (pH 7.4), 25 mM NaCl, 2 mM DDT, 20 mM Na2MoO4, 0.1% NP-
40, and protein inhibitors. Lysates were incubated for 2 hr at 4C, rotating,
and then centrifuged at 13,0003 g for 10min. Protein (500 mg) was incubated
with H9010 anti-HSP90 antibody for 1 hr at 4C, rotating. Protein G agarose
(30 ml; Upstate) was added to each sample, and samples were then incu-
bated for 1 hr at 4C, rotating. The beads were washed five times with 1 ml
lysis buffer. Bound proteins were isolated by boiling in sample buffer. The
levels of HSP90 and coimmunoprecipitating proteins were analyzed by
western blot.CANCER CELL OCTOBER 2006Geldanamycin competition assay
The geldanamycin competition assay was performed as described (He et al.,
2006; Kim et al., 2004), except that Cy3B-geldanamycin rather than BODIPY-
geldanamycin was used (Supplemental Experimental Procedures).
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures,
nine supplemental tables, and three supplemental figures and can be found
with this article online at http://www.cancercell.org/cgi/content/full/10/4/
321/DC1/.
Acknowledgments
We thank Jane Jiang, James Griffin, Azam Mohammad, and George Daley
for Ba/F3 cell lines and Phil Febbo for use of microarray data from andro-
gen-stimulated and -deprived LNCaP cells. hHSP90 H9010, Hop F5, and
p23 JJ3 antibodies were a generous gift from David O. Toft. This work was
supported by a Damon Runyon fellowship to H.H. and NIH and HHMI grants
to T.R.G. In compliance with HMS guidelines, we disclose that W.C.H. is
a consultant for Novartis Pharmaceuticals, Inc.
Received: June 15, 2006
Revised: August 30, 2006
Accepted: September 13, 2006
Published online: September 28, 2006
References
Bagatell, R., Beliakoff, J., David, C.L., Marron, M.T., and Whitesell, L. (2005).
Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor
cells and demonstrate synergistic anticancer activity with cisplatin. Int. J.
Cancer 113, 179–188.
Bali, P., Pranpat, M., Bradner, J., Balasis, M., Fiskus, W., Guo, F., Rocha, K.,
Kumaraswamy, S., Boyapalle, S., Atadja, P., et al. (2005). Inhibition of histone
deacetylase 6 acetylates and disrupts the chaperone function of heat shock
protein 90: A novel basis for antileukemia activity of histone deacetylase in-
hibitors. J. Biol. Chem. 280, 26729–26734.
Chen, C.D., Welsbie, D.S., Tran, C., Baek, S.H., Chen, R., Vessella, R., Rose-
nfeld, M.G., and Sawyers, C.L. (2004). Molecular determinants of resistance
to antiandrogen therapy. Nat. Med. 10, 33–39.
di Bernardo, D., Thompson, M.J., Gardner, T.S., Chobot, S.E., Eastwood,
E.L., Wojtovich, A.P., Elliott, S.J., Schaus, S.E., and Collins, J.J. (2005). Che-
mogenomic profiling on a genome-wide scale using reverse-engineered
gene networks. Nat. Biotechnol. 23, 377–383.
Ebert, B.L., Lee, M.M., Pretz, J.L., Subramanian, A., Mak, R., Golub, T.R.,
and Sieff, C.A. (2005). An RNA interference model of RPS19 deficiency in Di-
amond-Blackfan anemia recapitulates defective hematopoiesis and rescue
by dexamethasone: Identification of dexamethasone-responsive genes by
microarray. Blood 105, 4620–4626.
Febbo, P.G., Lowenberg, M., Thorner, A.R., Brown, M., Loda, M., and Golub,
T.R. (2005). Androgen mediated regulation and functional implications of
fkbp51 expression in prostate cancer. J. Urol. 173, 1772–1777.
Feldman, B.J., and Feldman, D. (2001). The development of androgen-inde-
pendent prostate cancer. Nat. Rev. Cancer 1, 34–45.
Felts, S.J., and Toft, D.O. (2003). p23, a simple protein with complex activi-
ties. Cell Stress Chaperones 8, 108–113.
Ficker, E., Dennis, A.T., Wang, L., and Brown, A.M. (2003). Role of the cyto-
solic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium
channel HERG. Circ. Res. 92, e87–e100.
Figueiredo, J.N., Raz, B., and Sequin, U. (1998). Novel quinone methides
from Salacia kraussii with in vitro antimalarial activity. J. Nat. Prod. 61,
718–723.
Gardner, T.S., di Bernardo, D., Lorenz, D., and Collins, J.J. (2003). Inferring
genetic networks and identifying compound mode of action via expression
profiling. Science 301, 102–105.329
A R T I C L EGeorget, V., Terouanne, B., Nicolas, J.C., and Sultan, C. (2002). Mechanism
of antiandrogen action: Key role of hsp90 in conformational change and tran-
scriptional activity of the androgen receptor. Biochemistry 41, 11824–11831.
Gessner, P.K. (1995). Isobolographic analysis of interactions: An update on
applications and utility. Toxicology 105, 161–179.
Golub, T.R., Slonim, D.K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov,
J.P., Coller, H., Loh, M.L., Downing, J.R., Caligiuri, M.A., et al. (1999). Molec-
ular classification of cancer: Class discovery and class prediction by gene
expression monitoring. Science 286, 531–537.
Hahn, W.C., Counter, C.M., Lundberg, A.S., Beijersbergen, R.L., Brooks,
M.W., and Weinberg, R.A. (1999). Creation of human tumour cells with de-
fined genetic elements. Nature 400, 464–468.
He, H., Zatorska, D., Kim, J., Aguirre, J., Llauger, L., She, Y., Wu, N., Immor-
mino, R.M., Gewirth, D.T., and Chiosis, G. (2006). Identification of potent wa-
ter soluble purine-scaffold inhibitors of the heat shock protein 90. J. Med.
Chem. 49, 381–390.
Holzbeierlein, J., Lal, P., LaTulippe, E., Smith, A., Satagopan, J., Zhang, L.,
Ryan, C., Smith, S., Scher, H., Scardino, P., et al. (2004). Gene expression
analysis of human prostate carcinoma during hormonal therapy identifies an-
drogen-responsive genes and mechanisms of therapy resistance. Am. J.
Pathol. 164, 217–227.
Hughes, T.R., Marton, M.J., Jones, A.R., Roberts, C.J., Stoughton, R., Ar-
mour, C.D., Bennett, H.A., Coffey, E., Dai, H., He, Y.D., et al. (2000). Func-
tional discovery via a compendium of expression profiles. Cell 102, 109–126.
Kim, J., Felts, S., Llauger, L., He, H., Huezo, H., Rosen, N., and Chiosis, G.
(2004). Development of a fluorescence polarization assay for the molecular
chaperone Hsp90. J. Biomol. Screen. 9, 375–381.
Kovacs, J.J., Murphy, P.J., Gaillard, S., Zhao, X., Wu, J.T., Nicchitta, C.V.,
Yoshida, M., Toft, D.O., Pratt, W.B., and Yao, T.P. (2005). HDAC6 regulates
Hsp90 acetylation and chaperone-dependent activation of glucocorticoid
receptor. Mol. Cell 18, 601–607.
Lam, J.S., Leppert, J.T., Vemulapalli, S.N., Shvarts, O., and Belldegrun, A.S.
(2006). Secondary hormonal therapy for advanced prostate cancer. J. Urol.
175, 27–34.
Lamb, J., Ramaswamy, S., Ford, H.L., Contreras, B., Martinez, R.V., Kittrell,
F.S., Zahnow, C.A., Patterson, N., Golub, T.R., and Ewen, M.E. (2003). A
mechanism of cyclin D1 action encoded in the patterns of gene expression
in human cancer. Cell 114, 323–334.
Lamb, J., Crawford, E.D., Peck, D., Modell, J.W., Blat, I.C., Wrobel, M.J.,
Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K.N., et al. (2006). The con-
nectivity map: Using gene-expression signatures to connect small mole-
cules, genes and disease. Science, in press.
Linja, M.J., Savinainen, K.J., Saramaki, O.R., Tammela, T.L., Vessella, R.L.,
and Visakorpi, T. (2001). Amplification and overexpression of androgen re-
ceptor gene in hormone-refractory prostate cancer. Cancer Res. 61, 3550–
3555.
Llauger-Bufi, L., Felts, S.J., Huezo, H., Rosen, N., and Chiosis, G. (2003).
Synthesis of novel fluorescent probes for the molecular chaperone Hsp90.
Bioorg. Med. Chem. Lett. 13, 3975–3978.
MacKinnon, S., Durst, T., Arnason, J.T., Angerhofer, C., Pezzuto, J., San-
chez-Vindas, P.E., Poveda, L.J., and Gbeassor, M. (1997). Antimalarial activ-
ity of tropical Meliaceae extracts and gedunin derivatives. J. Nat. Prod. 60,
336–341.
Majumder, P.K., and Sellers, W.R. (2005). Akt-regulated pathways in pros-
tate cancer. Oncogene 24, 7465–7474.
Marcu, M.G., Schulte, T.W., and Neckers, L. (2000). Novobiocin and related
coumarins and depletion of heat shock protein 90-dependent signaling pro-
teins. J. Natl. Cancer Inst. 92, 242–248.
Mimnaugh, E.G., Xu, W., Vos, M., Yuan, X., Isaacs, J.S., Bisht, K.S., Gius, D.,
and Neckers, L. (2004). Simultaneous inhibition of hsp 90 and the protea-
some promotes protein ubiquitination, causes endoplasmic reticulum-de-
rived cytosolic vacuolization, and enhances antitumor activity. Mol. Cancer
Ther. 3, 551–566.330Murakami, Y., Uehara, Y., Yamamoto, C., Fukazawa, H., and Mizuno, S.
(1991). Induction of hsp 72/73 by herbimycin A, an inhibitor of transformation
by tyrosine kinase oncogenes. Exp. Cell Res. 195, 338–344.
Padma, T.V. (2005). Ayurveda. Nature 436, 486.
Parsons, A.B., Brost, R.L., Ding, H., Li, Z., Zhang, C., Sheikh, B., Brown,
G.W., Kane, P.M., Hughes, T.R., and Boone, C. (2004). Integration of chem-
ical-genetic and genetic interaction data links bioactive compounds to cellu-
lar target pathways. Nat. Biotechnol. 22, 62–69.
Peck, D., Crawford, E.D., Ross, K.N., Stegmaier, K., Golub, T.R., and Lamb,
J. (2006). A method for high-throughput gene expression signature analysis.
Genome Biol. 7, R61.
Reich, M., Liefeld, T., Gould, J., Lerner, J., Tamayo, P., and Mesirov, J.P.
(2006). GenePattern 2.0. Nat. Genet. 38, 500–501.
Soti, C., Racz, A., and Csermely, P. (2002). A nucleotide-dependent molec-
ular switch controls ATP binding at the C-terminal domain of Hsp90. N-termi-
nal nucleotide binding unmasks a C-terminal binding pocket. J. Biol. Chem.
277, 7066–7075.
Stegmaier, K., Ross, K.N., Colavito, S.A., O’Malley, S., Stockwell, B.R., and
Golub, T.R. (2004). Gene expression-based high-throughput screening (GE-
HTS) and application to leukemia differentiation. Nat. Genet. 36, 257–263.
Sun, H., Liu, X., Xiong, Q., Shikano, S., and Li, M. (2006). Chronic inhibition of
cardiac kir2.1 andHERGpotassium channels by celastrol with dual effects on
both ion conductivity and protein trafficking. J. Biol. Chem. 281, 5877–5884.
Ushiro, S., Ono, M., Nakayama, J., Fujiwara, T., Komatsu, Y., Sugimachi, K.,
and Kuwano, M. (1997). New nortriterpenoid isolated from anti-rheumatoid
arthritic plant, Tripterygium wilfordii, modulates tumor growth and neovascu-
larization. Int. J. Cancer 72, 657–663.
Vilenchik, M., Solit, D., Basso, A., Huezo, H., Lucas, B., He, H., Rosen, N.,
Spampinato, C., Modrich, P., and Chiosis, G. (2004). Targeting wide-range
oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90.
Chem. Biol. 11, 787–797.
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinanen, R., Palmberg,
C., Palotie, A., Tammela, T., Isola, J., and Kallioniemi, O.P. (1995). In vivo am-
plification of the androgen receptor gene and progression of human prostate
cancer. Nat. Genet. 9, 401–406.
Walsh, P.C. (1996). Treatment of benign prostatic hyperplasia. N. Engl. J.
Med. 335, 586–587.
Wang, J., Gines, S., MacDonald, M.E., and Gusella, J.F. (2005). Reversal of
a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors
of polyglutamine-mediated aggregation. BMC Neurosci. 6, 1.
Waza, M., Adachi, H., Katsuno, M., Minamiyama, M., Sang, C., Tanaka, F.,
Inukai, A., Doyu, M., and Sobue, G. (2005). 17-AAG, an Hsp90 inhibitor, ame-
liorates polyglutamine-mediated motor neuron degeneration. Nat. Med. 11,
1088–1095.
Westerheide, S.D., Bosman, J.D., Mbadugha, B.N., Kawahara, T.L., Matsu-
moto, G., Kim, S., Gu, W., Devlin, J.P., Silverman, R.B., and Morimoto, R.I.
(2004). Celastrols as inducers of the heat shock response and cytoprotec-
tion. J. Biol. Chem. 279, 56053–56060.
Whitesell, L., and Lindquist, S.L. (2005). HSP90 and the chaperoning of can-
cer. Nat. Rev. Cancer 5, 761–772.
Yang, H., Chen, D., Cui, Q.C., Yuan, X., and Dou, Q.P. (2006). Celastrol, a tri-
terpene extracted from the Chinese ‘‘Thunder of God Vine,’’ is a potent pro-
teasome inhibitor and suppresses human prostate cancer growth in nude
mice. Cancer Res. 66, 4758–4765.
Zhao, R., Davey, M., Hsu, Y.C., Kaplanek, P., Tong, A., Parsons, A.B., Kro-
gan, N., Cagney, G.,Mai, D., Greenblatt, J., et al. (2005). Navigating the chap-
erone network: An integrative map of physical and genetic interactions me-
diated by the hsp90 chaperone. Cell 120, 715–727.
Accession numbers
The Affymetrix data presented here are available from NCBI’s Gene Expres-
sion Omnibus as series GSE5505 to GSE5508 (LNCaP data) and GSE5258
(Connectivity Map).CANCER CELL OCTOBER 2006
